

Prostate Cancer Committee meeting

Date: 21/05/2018 – 22/05/2018

Location: NICE offices, Manchester

Minutes: Final

Committee members present:		
	Day 1	Day 2
Waqar Shah (WS) (Chair)	Present for all	Present for all
Abi Ademoyero (AA)	Apologies	Present for all
Pauline Bagnall (PB)	Present for all	Present for all
Guy Chetiyawardana (GC)	Present for all	Present for all
Charles Frost (CF)	Present for all	Present for all
John Graham (JG)	Present for all	Present for all
Sadaf Haque (SH)	Present for all	Apologies
Peter Jenkins (PJ)	Present from partway through item 3	Present until partway through item 3
Howard Kynaston (HK)	Present for all	Present for all
Sanjeev Madaan (SM)	Apologies	Present for all
Jon Oxley (JO)	Present for all	Present for all
Jonathan Richenberg (JR)	Present for all	Present for all
Mark Robinson (MR)	Present for all	Present for all
Karen Stalbow (KS)	Present from item 4	Present for all

In attendance:		
	Day 1	Day 2
Jean Bennie (JB) GUT – Technical Analyst	Present for all	Present for all
Chris Carmona (CC) GUT – Senior Technical Analyst	Present for all	Present for all
Clare Dadswell (CD) GUT – Technical Analyst	Present for all	Present from partway through item 2
Rupert Franklin (RF) NICE – Senior Guidelines Commissioning Manager	Present for all	Present from item 3
Gareth Haman (GH) NICE – Senior Medical Editor	Apologies	Present for all
Jenny Kendrick (JK) NICE – Information Specialist	Present from afternoon break	Apologies
Adam O’Keefe (AO) GUT - Project Manager	Present for all	Present for all
Gabriel Rogers (GR)	Present for all	Present for all

NICE - Technical Adviser (HE)		
-------------------------------	--	--

Observer:		
Alice Biggane		Present for all on both days

Apologies:		
Brian McGlynn – Committee member		
Fadi Chehadah – NICE – Health Economist		

Day 1 Monday 21 May 2018:

1. Welcome, apologies, minutes of the last meeting, declarations of interest
<p>The Chair welcomed the Committee members and attendees to the day 1 of the sixth meeting on Prostate cancer. The Chair introduced CD as a new Technical Analyst in the Guideline Updates Team who will present clinical evidence identified for Review Question 1. The Committee members and attendees introduced themselves.</p> <p>Apologies for the meeting were received as detailed above. The Chair advised that KS was absent from the morning session due to a conflict of interest relevant to the topic being discussed under items 2 and 3.</p> <p>The Chair explained that as the previous committee meeting had not been quorate, the committee would revisit review questions 1 and 3, presented at that meeting, to draft recommendations. There would then be clinical evidence presented for review question 8, however recommendations for this question would not be drafted until the final meeting, once the committee had considered the health economic evidence.</p> <p>The minutes of the previous meeting were agreed as an accurate record.</p> <p>Each committee member was asked to declare any new conflicts since the previous meeting. No new interests were declared. The Chair confirmed that, having reviewed the historical declaration of interests table that the remaining committee members present were eligible to attend the committee meeting and contribute to the discussions and drafting of any recommendations.</p>
2. Review Question 1: Which of the following, alone or in combination, constitutes the most clinical and cost- effective pathway for diagnosing prostate cancer: Multiparametric MRI; Transrectal ultrasonography (TRUS) biopsy; Transperineal template biopsy? (Diagnostic test accuracy)
<p>The Chair welcomed JB to recap the clinical evidence identified for this question presented at the previous meeting.</p> <p>The committee considered the evidence presented and drafted two recommendations.</p>

3. Review Question 1(a): Which of the following, alone or in combination, constitutes the most clinical and cost- effective pathway for diagnosing prostate cancer: Multiparametric MRI; Transrectal ultrasonography (TRUS) biopsy; Transperineal template biopsy? (RCTs)

Following the committee's request to amend the review protocol for review question 1 to include randomised control trials, CD presented the identified evidence for these type of studies for the committee's consideration.

The committee considered the evidence presented for both study designs and drafted seven recommendations.

4. Review Question 8 What is the most clinically- and cost-effective follow-up protocol for people who have a raised PSA, negative MRI and/ or negative biopsy?

JB presented the clinical evidence identified for Review Question 8 for the Committee's consideration. The Committee discussed the evidence and agreed to continue their discussions following presentation of the published and original Health economic evidence on the topic.

5. Next steps

The Chair thanked the committee for their input and confirmed day 2 would commence at 10am as scheduled.

Day 2 Tuesday 22 May 2018:

1. Welcome, apologies, declarations of interest

The Chair welcomed the Committee members and attendees to day two of the sixth meeting of the prostate cancer guideline committee. Apologies for the meeting were received as detailed above.

The Chair outlined the main objectives of the day, which included an update on development of the Health Economic model and a review of recommendations drafted to date.

Each committee member was asked to any new conflicts. No new interests were declared. The Chair confirmed that the committee members present were eligible to attend the committee meeting and contribute to the discussions and drafting of any recommendations.

2. HE model update

GR discussed developments with the health economic model being constructed with the committee and checked with it that some of the assumptions made were reasonable.

3. Review of edited recommendations drafted to date

Following editorial review by GH, the committee revisited recommendations drafted to date, revising them as necessary.

4. Next steps

The Chair confirmed the venue, date and time of the next meeting, as detailed below and thanked the Committee and others present for their contribution to the meeting before closing the meeting.

Date of next meeting: 10 / 11 July 2018

Location of next meeting: NICE - London